Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: Analysis of effects of baseline features on treatment response

BMC Geriatrics

Volumn 13, Issue 1, 2013, Pages

  Sabbagh, Marwan ^a   Cummings, Jeffrey ^b   Christensen, Daniel ^c   Doody, Rachelle ^d   Farlow, Martin ^e   Liu, Liang ^f   Mackell, Joan ^g   Fain, Randi ^f  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

^b CLEVELAND CLINIC LOU RUVO CENTER FOR BRAIN HEALTH   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f EISAI INC   (United States)

^g PFIZER INC   (United States)

Author keywords

Alzheimer's disease; Cognitive dysfunction; Donepezil; Severe impairment battery (SIB)

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; INDAN DERIVATIVE; PIPERIDINE DERIVATIVE;

AGED; ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITION DISORDERS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VERY ELDERLY; ARTICLE; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; PSYCHOLOGICAL ASPECT;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDANS; MALE; MIDDLE AGED; PIPERIDINES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84878507678     PISSN: None     EISSN: 14712318     Source Type: Journal    
DOI: 10.1186/1471-2318-13-56     Document Type: Article

References (25)

1. Reviewing the role of donepezil in the treatment of Alzheimer's disease. Doody RS, Cummings JL, Farlow MR, Curr Alzheimer Res 2012 9 773 781 10.2174/156720512802455412 22175653
2. Donepezil for dementia due to Alzheimer's disease. Birks JS, Harvey R, Cochrane Database Syst Rev 2003 3 D001190 12917900
3. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials. Whitehead A, Perdomo C, Pratt RD, Birks J, Wilcock GK, Evans JG, Int J Geriatr Psychiatry 2004 19 624 633 10.1002/gps.1133 15254918
4. Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trial. Homma A, Imai Y, Tago H, Asada T, Shigeta M, Iwamoto T, Takita M, Arimoto I, Koma H, Ohbayashi T, Dement Geriatr Cogn Disord 2008 25 399 407 10.1159/000122961 18391486
5. Clinical effects of high oral dose of donepezil for patients with Alzheimer's disease in Japan. Nozawa M, Ichimiya Y, Nozawa E, Utumi Y, Sugiyama H, Murayama N, Iseki E, Arai H, Psychogeriatrics 2009 9 50 55 10.1111/j.1479-8301.2009.00291.x 19604325
6. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: a 24-week, randomized, double-blind study. Farlow MR, Salloway S, Tariot PN, Yardley J, Moline ML, Wang Q, Brand-Schieber E, Zou H, Hsu T, Satlin A, Clin Ther 2010 32 1234 1251 10.1016/j.clinthera.2010.06.019 20678673
7. Donepezil treatment in severe Alzheimer's disease: a pooled analysis of three clinical trials. Winblad B, Black SE, Homma A, Schwam EM, Moline M, Xu Y, Perdomo CA, Swartz J, Albert K, Curr Med Res Opin 2009 25 2577 2587 19735164
8. Sustained cognitive improvement following treatment of Alzheimer's disease with donepezil. Evans M, Ellis A, Watson D, Chowdhury T, Int J Geriatr Psychiatry 2000 15 50 53 10.1002/(SICI)1099-1166(200001)15:1<50::AID- GPS75>3.0.CO;2-M 10637404
9. Predicting the outcome of cholinesterase inhibitor treatment in Alzheimer's disease. Connelly PJ, Prentice NP, Fowler KG, J Neurol Neurosurg Psychiatry 2005 76 320 324 10.1136/jnnp.2004.043539 15716519
10. Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Farlow MR, Hake A, Messina J, Hartman R, Veach J, Anand R, Arch Neurol 2001 58 417 422 10.1001/archneur.58.3. 417 11255445
11. Galantamine: additional benefits to patients with Alzheimer's disease. Lilienfeld S, Parys W, Dement Geriatr Cogn Disord 2000 11 19 27 10.1159/000051228 10971048
12. Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine. Doody RS, Geldmacher DS, Farlow MR, Sun Y, Moline M, Mackell J, Dement Geriatr Cogn Disord 2012 33 164 173 10.1159/000338236 22572767
13. Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer's disease. Salloway S, Mintzer J, Cummings JL, Geldmacher D, Sun Y, Yardley J, Mackell J, Am J Alzheimers Dis Other Demen 2012 27 421 432 10.1177/1533317512454708 22930699
14. Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials. Bernick C, Cummings J, Raman R, Sun X, Aisen P, Arch Neurol 2012 69 901 905 10.1001/archneurol.2011.3758 22431834
15. Age at onset is associated with disease severity in Lewy body variant and Alzheimer's disease. Ho GJ, Hansen LA, Alford MF, Foster K, Salmon DP, Galasko D, Thal LJ, Masliah E, NeuroReport 2002 13 1825 1828 10.1097/00001756-200210070- 00028 12395133
16. The effects of age on rate of progression of Alzheimer disease and dementia with associated cerebrovascular disease. Mungas D, Reed BR, Ellis WG, Jagust WJ, Arch Neurol 2001 58 1243 1247 10.1001/archneur.58.8.1243 11493164
17. Most rapid cognitive decline in APOE epsilon4 negative Alzheimer's disease with early onset. Van der Vlies AE, Koedam EL, Pijnenburg YA, Twisk JW, Scheltens P, Van der Flier WM, Psychol Med 2009 39 1907 1911 10.1017/S0033291709005492 19335933
18. The prevalence of apoE-epsilon4 in Alzheimer's disease is age dependent. Frisoni GB, Manfredi M, Geroldi C, Binetti G, Zanetti O, Bianchetti A, Trabucchi M, J Neurol Neurosurg Psychiatry 1998 65 103 106 10.1136/jnnp.65.1.103 9667569
19. Influence of apolipoprotein E varepsilon4 on rates of cognitive and functional decline in mild cognitive impairment. Whitehair DC, Sherzai A, Emond J, Raman R, Aisen PS, Petersen RC, Fleisher AS, Alzheimers Dement 2010 6 412 419 10.1016/j.jalz.2009.12.003 20813342
20. Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease. Farlow M, Veloso F, Moline M, Yardley J, Brand-Schieber E, Bibbiani F, Zou H, Hsu T, Satlin A, BMC Neurol 2011 11 57 10.1186/1471-2377-11- 57 21612646
21. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, JAMA 2004 291 317 324 10.1001/jama.291.3.317 14734594
22. Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology. Sabbagh M, Cummings J, BMC Neurol 2011 11 21 10.1186/1471-2377-11-21 21299848
23. Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Kuhl DE, Minoshima S, Frey KA, Foster NL, Kilbourn MR, Koeppe RA, Ann Neurol 2000 48 391 395 10.1002/1531-8249(200009)48:3<391::AID-ANA17>3.0.CO;2-H 10976649
24. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. Kaasinen V, Nagren K, Jarvenpaa T, Roivainen A, Yu M, Oikonen V, Kurki T, Rinne JO, J Clin Psychopharmacol 2002 22 615 620 10.1097/00004714-200212000-00012 12454562
25. Cholinergic markers in elderly patients with early signs of Alzheimer disease. Davis KL, Mohs RC, Marin D, Purohit DP, Perl DP, Lantz M, Austin G, Haroutunian V, JAMA 1999 281 1401 1406 10.1001/jama.281.15.1401 10217056